triple hormone receptor agonist retatrutide for obesity 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide vs Survodutide: Triple vs

Description

Large outcome trials such as SELECT and FLOW have shown 20 percent reductions in cardiovascular and kidney complications in high-risk adults

Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as one of the most transformative therapeutic classes in modern medicine

Cardio IQ Apolipoprotein B

Acta Neuropsychiatr 37: e50

Semaglutide (2.4 mg/week), approved in 2021, delivers improved weight loss compared to the earlier treatments and represents considerable progress in obesity pharmacotherapy (13)